<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="821">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>12/09/2005</approvaldate>
  <nctid>NCT00192439</nctid>
  <trial_identification>
    <studytitle>Study to Evaluate the Human Infection of the Lower Respiratory Tract in Children at High Risk</studytitle>
    <scientifictitle>A Study to Describe the Incidence Rate and Clinical Features of Human Meta Pneumovirus (hMPV) Infection of the Lower Respiratory Tract in Hospitalized Children at High Risk for Severe Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MI-CP096</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Severe Respiratory Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Behaviour - High Risk Respiratory Disease

Behaviour: High Risk Respiratory Disease


</interventions>
    <comparator />
    <control />
    <interventioncode>Behaviour</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>-  Be premature (less than 36 weeks gestation) and less than or equal to 12 months of
             age, and/or

          -  Be less than or equal to 24 months of age with CHD (other than uncomplicated small
             atrial or ventricular septal defects or patent ductus arteriosus) that is judged to be
             hemodynamically significant, and/or

          -  Be less than or equal to 24 months of age with CLD of prematurity (BPD) requiring
             medical intervention/management (i.e., supplemental oxygen, steroids, bronchodilators,
             or diuretics within the previous 6 months).

          -  Hospital admission diagnosis referable to an acute lower respiratory tract infection
             or cardio/respiratory illness with a presumed respiratory infection (e.g.,
             bronchiolitis, bronchitis, or pneumonia or cardiac decompensation associated with
             respiratory infection); admission must occur between October 1 and June 30 for
             northern hemisphere sites, and between March 1 and November 30 for southern hemisphere
             sites.

          -  Study enrollment within 2 days after hospitalization.

          -  Admission from the community to the Pediatric ward, Neonatal Intensive Care Unit, or
             the Intensive Care Unit.

          -  Have written informed consent obtained from the parent or legal guardian prior to
             study entry.</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>24</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known HIV infection or a mother with known HIV infection.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration>Cross-sectional</duration>
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1500</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC,WA</recruitmentstate>
    <hospital>University Dept. of Paediatrics, Women's and Children's Hospital - North Adelaide</hospital>
    <hospital>Royal Children's Hospital, Murdoch Children's Research Institute - Parkville</hospital>
    <hospital>University of Western Australia - Perth</hospital>
    <postcode>5006 - North Adelaide</postcode>
    <postcode>3052 - Parkville</postcode>
    <postcode>6014 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>MedImmune LLC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>- Estimate the incidence rate of hMPV infection detected by RT-PCR from frozen nasal wash
      aspirates in children at high risk for severe LRI disease (hospitalized at &lt;2 years of age).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00192439</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Margarita Gomez, M.D.</name>
      <address>MedImmune LLC</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>